



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER OF PATENTS AND TRADEMARKS
Washington, D.C. 20231
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/736,968	12/13/2000	Peter S. Lu	020054-000611US	8280

20350 7590 11/20/2002

TOWNSEND AND TOWNSEND AND CREW, LLP
TWO EMBARCADERO CENTER
EIGHTH FLOOR
SAN FRANCISCO, CA 94111-3834

EXAMINER

BUNNER, BRIDGET E

ART UNIT	PAPER NUMBER
----------	--------------

1647

DATE MAILED: 11/20/2002

15

Please find below and/or attached an Office communication concerning this application or proceeding.

Office Action Summary

Application No.

09/736,968

Applicant(s)

LU ET AL.

Examiner

Bridget E. Bunner

Art Unit

1647

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133).
- Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) ☒ Responsive to communication(s) filed on 04 September 2002.
- 2a) ☐ This action is **FINAL**. 2b) ☒ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) ☒ Claim(s) 1-37 is/are pending in the application.
- 4a) Of the above claim(s) 5, 16-29 and 31-37 is/are withdrawn from consideration.
- 5) ☐ Claim(s) _____ is/are allowed.
- 6) ☒ Claim(s) 1-4, 6-15 and 30 is/are rejected.
- 7) ☐ Claim(s) _____ is/are objected to.
- 8) ☒ Claim(s) 1-37 are subject to restriction and/or election requirement.

Application Papers

- 9) ☒ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on _____ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.
- Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
- 11) ☐ The proposed drawing correction filed on _____ is: a) ☐ approved b) ☐ disapproved by the Examiner.
- If approved, corrected drawings are required in reply to this Office action.
- 12) ☐ The oath or declaration is objected to by the Examiner.

Priority under 35 U.S.C. §§ 119 and 120

- 13) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All b) ☐ Some * c) ☐ None of:
1. ☐ Certified copies of the priority documents have been received.
2. ☐ Certified copies of the priority documents have been received in Application No. _____.
3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).
- * See the attached detailed Office action for a list of the certified copies not received.
- 14) ☒ Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application).
- a) ☐ The translation of the foreign language provisional application has been received.
- 15) ☒ Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121.

Attachment(s)

- 1) ☒ Notice of References Cited (PTO-892)
- 2) ☐ Notice of Draftsperson's Patent Drawing Review (PTO-948)
- 3) ☐ Information Disclosure Statement(s) (PTO-1449) Paper No(s) _____.
- 4) ☐ Interview Summary (PTO-413) Paper No(s). _____.
- 5) ☐ Notice of Informal Patent Application (PTO-152)
- 6) ☐ Other: _____.

DETAILED ACTION

Status of Application, Amendments and/or Claims

The amendment of 12 October 2001 (Paper No. 8) has been entered in full.

Election/Restrictions

Applicant's election with traverse of Applicant's election without traverse of Group A, claims 1-4, 6-15, and 30, drawn to an isolated CLASP-7 polynucleotide, an expression vector, a host cell system, and a method of producing a CLASP-7 polypeptide in Paper No. 14 (04 September 2002) is acknowledged.

Applicant's election with traverse of Group A, claims 1-6, 8-17, and 32, drawn to an isolated CLASP-2 polynucleotide, an expression vector, a host cell system, and a method of producing a CLASP-2 polypeptide in Paper No. 13 (23 August 2002) is acknowledged. The traversal is on the ground(s) that Groups A, F, and G should be rejoined. This is not found persuasive because, as discussed in the previous Office Action (30 July 2002), the polynucleotide of Invention A can be used in materially different processes other than the methods of Groups F and G, such as DNA purification and gene therapy (MPEP § 086.05(h)). Each of groups A, F, and G are unique invention, requiring a unique search of the prior art. Searching all of the inventions in a single patent application would provide an undue search burden on the examiner and the USPTO's resources because of the non-coextensive nature of these searches.

The requirement is still deemed proper and is therefore made FINAL.

Claims 5, 16-29, and 31-37 are withdrawn from further consideration pursuant to 37 CFR 1.142(b), as being drawn to a nonelected group, there being no allowable generic or linking

claim. Applicant timely traversed the restriction (election) requirement in Paper No. 14 (04 September 2002).

It is noted to Applicant that although claims 28 and 29 may recite unintentional errors, Applicant must comply with 37 CFR 1.121 to make claim amendments.

Claims 1-4, 6-15, and 30 are under consideration in the instant application.

Specification

1. The disclosure is objected to because of the following informalities:
 - 1a. Patent applications are referenced throughout the disclosure (pg 2, line 7; pg 111, line 22).
 - 1b. The status of the applications must be updated.
 - 1c. The disclosure is objected to because it contains an embedded hyperlink and/or other form of browser-executable code (See page 12, line 17). Applicant is required to delete the embedded hyperlink and/or other form of browser-executable code. See MPEP § 608.01.
 - 1d. The specification is replete with blanks, which are not clear, concise, and exact (see for example, pages 3, 31, 111).
 - 1e. The Brief Description of Drawings refers to Figure 5C. However, Figure 5C is identified as Figure 5B (2 of 2) on the Drawing sheet.
 - 1f. The title of the invention is not descriptive. A new title is required that is clearly indicative of the invention to which the claims are directed.

The following title is suggested: "NUCLEIC ACID MOLECULE ENCODING A CLASP-7 TRANSMEMBRANE PROTEIN".

Appropriate correction is required.

Claim Objections

2. Claims 1 and 30 are objected to because of the following informalities:
 - 2a. Claim 1(c) at line 3 is missing the term “least” before the phrase “25 contiguous residues”.
 - 2b. Claim 30 recites non-elected groups.

Appropriate correction is required.

Claim Rejections - 35 USC § 101 and § 112, first paragraph

35 U.S.C. 101 reads as follows:

Whoever invents or discovers any new and useful process, machine, manufacture, or composition of matter, or any new and useful improvement thereof, may obtain a patent therefore, subject to the conditions and requirements of this title.

The following is a quotation of the first paragraph of 35 U.S.C. 112:

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

3. Claims 1-4, 6-15, and 30 are rejected under 35 U.S.C. 101 because the claimed invention is not supported by either a credible, specific and substantial asserted utility or a well established utility. Novel biological molecules lack well established utility and must undergo extensive experimentation.

Specifically, claims 1-4, 6-15, and 30 are directed to an isolated Cadherin-like asymmetry protein-7 (CLASP-7) polynucleotide wherein the polynucleotide is (a) a polynucleotide that has the sequence of SEQ ID NO: 1, (b) a polynucleotide that hybridizes under stringent hybridization conditions to (a) and encodes a polypeptide having the sequence of SEQ ID NO: 2 or an allelic variant or homologue, (c) a polynucleotide that hybridizes under stringent hybridization conditions to (a) and encodes a polypeptide with at least 25 contiguous residues of the

Art Unit: 1647

polypeptide of SEQ ID NO: 2, or (d) a polynucleotide that hybridizes under stringent hybridization conditions to (a) and has at least 12 contiguous bases identical to or exactly complementary to SEQ ID NO: 1. The claims further recite that the polynucleotide encodes a polypeptide having the sequence of SEQ ID NO: 2. The claims recite an isolated CLASP-7 polynucleotide comprising a nucleotide sequence that has at least 90% identity to SEQ ID NO: 1. The claims also recite an expression vector comprising the polynucleotide, a host cell, and a method for producing the polypeptide. Additionally, the claims are directed to an antisense oligonucleotide complementary to a mRNA comprising SEQ ID NO: 1 and an antisense polynucleotide less than about 200 bases in length. The claims recite a pharmaceutical composition comprising a polynucleotide and a pharmaceutically acceptable carrier.

The specification asserts that the CLASP-7 polynucleotide (SEQ ID NO:1) and polypeptide (SEQ ID NO: 2) of the present invention are involved in a variety of cellular processes, particularly related to immune function, T cell activation, regulation of T cell and B cell interactions, and in the organization, establishment, and maintenance of the “immunological synapse” (including signal transduction, cytoskeletal interactions, and membrane organization) (pg 18, lines 6-13). The specification also discloses that the CLASP-7 protein is believed to be a component of the lymphocyte organelle called the “immune gateway” that creates a docking site or portal for cell-cell contact during antigen presentation (pg 18, lines 14-17). However, the instant specification does not teach any significance or functional characteristics of the CLASP-7 polynucleotide (SEQ ID NO: 1) or polypeptide (SEQ ID NO: 2). The specification also does not disclose any methods or working examples that indicate the polynucleotide and polypeptide of the instant invention are involved in any of the abovementioned activities. Since significant

further research would be required of the skilled artisan to determine how the claimed polypeptide is involved with the above-mentioned activities, the asserted utilities are not substantial. Since the utility is not presented in mature form and significant further research is required, the utility is not substantial. The specification asserts the following as patentable utilities for the claimed putative polynucleotide (SEQ ID NO: 1):

- 1) to detect the expression of CLASP-7 in cells (pg 41, lines 32-33; pg 42; pg 48-50; pg 76-77)
- 2) in the diagnosis of a disorder or disease resulting from aberrant expression of CLASP-7 (pg 42, lines 1-9)
- 3) as hybridization probes for cDNA and genomic DNA (pg 42, lines 20-33; pg 44; pg 45, lines 1-25)
- 4) as primers for a nucleic acid amplification pg 43, lines 20-33; pg 44; pg 45, lines 1-25)
- 5) to treat, detect, or modulate immune system disorders, hematopoietic cell disorders, allergic reactions, organ rejection or graft-versus-host disease, inflammation, infectious agents (pg 44, lines 26-34; 45-47)
- 6) to engineer hammerhead motif ribozyme molecules (pg 54, lines 33-34; pg 55, lines 1-13)
- 7) for gene therapy (pg 55-60)
- 8) to construct a transgenic animal (pg 61-62)
- 9) in chromosome mapping (pg 62, lines 25-34; pg 63-64)
- 10) to screen CLASP-7 agonists and antagonists (pg 40, lines 32-33; pg 41, lines 1-2)

Each of these shall addressed in turn.

1) to detect the expression of CLASP-7 in cells. This asserted utility is credible, but not specific or substantial. The specification does not disclose a specific target sequence. The specification does not disclose the cell types that express CLASP-7. Significant further

Art Unit: 1647

experimentation would be required of the skilled artisan to identify cells with CLASP-7. Since this asserted utility is also not present in mature form so that it could be readily used in real world sense, the asserted utility is not substantial.

2) *in the diagnosis of a disorder or disease resulting from aberrant expression of CLASP-7.* This asserted utility is credible but not specific or substantial. The specification does not disclose disorders associated with a mutated, deleted, or translocated CLASP-7 gene. Significant further experimentation would be required of the skilled artisan to identify individuals with such a disease. Since this asserted utility is also not present in mature form so that it could be readily used in real world sense, the asserted utility is not substantial.

3) *as hybridization probes for cDNA and genomic DNA.* This asserted utility is credible but not substantial or specific. Hybridization probes can be designed from any polynucleotide sequence. Further, the specification does not disclose specific cDNA, DNA, or RNA targets. Since this asserted utility is also not present in mature form, so that it could be readily used in a real world sense, the asserted utility is not substantial.

4) *as primers for a nucleic acid amplification.* This asserted utility is credible but not substantial or specific. Primers can be designed from any polynucleotide sequence. Further, the specification does not disclose a specific DNA target. Since this asserted utility is also not present in mature form, so that it could be readily used in a real world sense, the asserted utility is not substantial.

5) *to treat, detect, or modulate immune system disorders, hematopoietic cell disorders, allergic reactions, organ rejection or graft-versus-host disease, inflammation, infectious agents.*

This asserted utility is credible but not specific or substantial. The specification does not

disclose disorders associated with a mutated, deleted, or translocated CLASP-7 gene (SEQ ID NO: 1). The specification does not disclose which disorders are associated with altered levels of the CLASP-7 gene. Significant further experimentation would be required of the skilled artisan to identify individuals with such a disease. Since this asserted utility is also not present in mature form, so that it could be readily used in a real world sense, the asserted utility is not substantial.

6) *to engineer hammerhead motif ribozyme molecules.* This asserted utility is credible but not specific or substantial. Ribozymes can be designed from any DNA/RNA sequence. Additionally, the specification does not disclose a specific DNA/RNA target. Since this asserted utility is also not present in mature form, so that it could be readily used in a real world sense, the asserted utility is not substantial.

7) *for gene therapy.* This asserted utility is not credible, specific or substantial. The specification does not disclose diseases associated with a mutated, deleted, or translocated CLASP-7 gene of SEQ ID NO: 1. Significant further experimentation would be required of the skilled artisan to identify individuals with such a disease. Since this asserted utility is also not presented in mature form, so that it could be readily used in a real world sense, the asserted utility is not substantial.

8) *to construct a transgenic animal.* This asserted utility is credible but not specific or substantial. The specification does not disclose diseases associated with a mutated, deleted, or translocated CLASP-7 gene (SEQ ID NO: 1). Significant further experimentation would be required of the skilled artisan to identify such a disease. The specification discloses nothing about whether the gene will be “knocked in” or “knocked out” or what specific tissues and cells

Art Unit: 1647

are being targeted. Since this asserted utility is also not present in mature form, so that it could be readily used in a real world sense, the asserted utility is not substantial.

9) *in chromosome mapping*. This asserted utility is credible but not substantial or specific. Such assays can be performed with any polynucleotide. Further, the specification does not disclose a specific DNA target. Since this asserted utility is also not present in mature form, so that it could be readily used in a real world sense, the asserted utility is not substantial.

10) *to screen CLASP-7 agonists and antagonists*. This asserted utility is credible but not specific or substantial. Such assays can be performed with any polynucleotide. Nothing is disclosed about how the polynucleotide is affected by the compounds. Additionally, the specification discloses nothing specific or substantial for the CLASP-7 agonists and antagonists screened in this method. Since this asserted utility is also not presented in mature form, so that it could be readily used in a real world sense, the asserted utility is not substantial.

4. Claims 1-4, 6-15, and 30 are also rejected under 35 U.S.C. 112, first paragraph. Specifically, since the claimed invention is not supported by either a specific and substantial asserted utility or a well established utility for the reasons set forth above, one skilled in the art clearly would not know how to use the claimed invention.

5. Furthermore, claims 1-4, 6-11, 14-15, and 30 recite a CLASP-7 polynucleotide wherein the polynucleotide is a polynucleotide that hybridizes under stringent hybridization conditions to (a) and encodes a polypeptide having the sequence of SEQ ID NO: 2 or an allelic variant or homologue, a polynucleotide that hybridizes under stringent hybridization conditions to (a) and encodes a polypeptide with at least 25 contiguous residues of the polypeptide of SEQ ID NO: 2, or (d) a polynucleotide that hybridizes under stringent hybridization conditions to (a) and has at

least 12 contiguous bases identical to or exactly complementary to SEQ ID NO: 1. The claims also recite an isolated CLASP-7 polynucleotide comprising a nucleotide sequence that has at least 90% identity to SEQ ID NO: 1. Additionally, the claims are directed to an antisense polynucleotide less than about 200 bases in length.

The specification discloses that “the CLASP-7 variants of the invention can contain alterations in the coding regions, non-coding regions, or both” (pg 38, lines 19-20). The specification teaches that known methods of protein engineering and recombinant DNA technology can generate variants to improve or alter the characteristics of the CLASP-7 polypeptides (pg 39, lines 9-11). However, the specification does not teach any allelic variants or homologs of the CLASP-7 polynucleotide or polypeptide. The specification does not disclose (i) a polynucleotide that encodes a polypeptide with at least 25 contiguous residues of the polypeptide of SEQ ID NO: 2, (ii) a polynucleotide that has at least 12 contiguous bases identical to or exactly complementary to SEQ ID NO: 1, or (iii) an antisense polynucleotide less than about 200 bases in length. The specification also does not teach a nucleic acid sequence with 90% sequence identity to the nucleotide sequence of SEQ ID NO: 1. Furthermore, regarding allelic variants, it is noted that such are recognized in the art as variant genes which map to the same locus on the chromosome (See Lewin, Genes II, 1985, pg 681). The specification does not disclose the chromosomal location of any of CLASP-7 gene characterized by the inventors. Additionally, the specification does not teach functional or structural characteristics of any polynucleotide variants in the context of a cell or organism.

Generally, the art acknowledges that function cannot be predicted based solely on structural similarity to a protein found in the sequence databases. For example, Skolnick et al.

Art Unit: 1647

(2000, Trends in Biotech. 18:34-39) state that knowing the protein structure by itself is insufficient to annotate a number of functional classes, and is also insufficient for annotating the specific details of protein function (see Box 2, p. 36). Similarly, Bork (2000, Genome Research 10:398-400) states that the error rate of functional annotations in the sequence database is considerable, making it even more difficult to infer correct function from a structural comparison of a new sequence with a sequence database (see especially p. 399). Such concerns are also echoed by Doerks et al. (1998, Trends in Genetics 14:248-250) who state that (1) functional information is only partially annotated in the database, ignoring multi functionality, resulting in underpredictions of functionality of a new protein and (2) overpredictions of functionality occur because structural similarity often does not necessarily coincide with functional similarity. Smith et al. (1997, Nature Biotechnology 15:1222-1223) remark that there are numerous cases in which proteins having very different functions share structural similarity due to evolution from a common ancestral gene. Brenner (1999, Trends in Genetics 15:132-133) argues that accurate inference of function from homology must be a difficult problem since, assuming there are only about 1000 major gene superfamilies in nature, then most homologs must have different molecular and cellular functions. Finally, Bork et al. (1996, Trends in Genetics 12:425-427) add that the software robots that assign functions to new proteins often assign a function to a whole new protein based on structural similarity of a small domain of the new protein to a small domain of a known protein. Such questionable interpretations are written into the sequence database and are then considered facts.

Therefore, based on the discussions above concerning the specific examples of structurally similar proteins that have different functions, along with the art's recognition that

Art Unit: 1647

one cannot rely upon structural similarity alone to determine functionality, the specification fails to teach the skilled artisan how to use the claimed polynucleotide to make biologically active CLASP-7 without resorting to undue experimentation to determine what the specific biological activities of the polypeptide are.

The specification does not teach the skilled artisan how to use the claimed polynucleotides encoding CLASP-7 for purposes unrelated to the asserted biological activity. For example, there is no disclosure of particular disease states correlating to an alteration in levels or forms of the polypeptide such that the claimed polynucleotide encoding CLASP-7 could be used as a diagnostic tool. Therefore, the skilled artisan is not provided with sufficient guidance to use the claimed polynucleotides for any purpose.

Further, the problem of predicting protein and DNA structure from sequence data and in turn utilizing predicted structural determinations to ascertain functional aspects of the protein and DNA is extremely complex. For example, while it is known that many amino acid substitutions are generally possible in any given protein the positions within the protein's sequence where such amino acid substitutions can be made with a reasonable expectation of success are limited. Certain positions in the sequence are critical to the protein's structure/function relationship, e.g. such as various sites or regions directly involved in binding, activity and in providing the correct three-dimensional spatial orientation of binding and active sites. These or other regions may also be critical determinants of antigenicity. These regions can tolerate only relatively conservative substitutions or no substitutions (see Wells, 1990, *Biochemistry* 29:8509-8517; Ngo et al., 1994, *The Protein Folding Problem and Tertiary Structure Prediction*, pp. 492-495). However, Applicant has provided little or no guidance beyond the mere presentation of sequence data to

enable one of ordinary skill in the art to determine, without undue experimentation, the positions in the protein and DNA which are tolerant to change and the nature and extent of changes that can be made in these positions. The art recognizes that function cannot be predicted from structure alone (Bork, 2000, Genome Research 10:398-400; Skolnick et al., 2000, Trends in Biotech. 18(1):34-39, especially p. 36 at Box 2; Doerks et al., 1998, Trends in Genetics 14:248-250; Smith et al., 1997, Nature Biotechnology 15:1222-1223; Brenner, 1999, Trends in Genetics 15:132-133; Bork et al., 1996, Trends in Genetics 12:425-427).

Furthermore, claim 30 is directed to a pharmaceutical composition comprising a CLASP-7 polynucleotide and a pharmaceutically acceptable carrier. The specification teaches a composition comprising an isolated CLASP-7 polynucleotide consisting of the nucleic acid sequence of SEQ ID NO: 1. The specification does not teach how to use a CLASP-7 “pharmaceutical” composition and a “pharmaceutically acceptable carrier” without undue experimentation for the treatment of a disease in an animal. The specification lists disorders to be treated (pg 44-47), but there are no working examples directed to a particular disorder in an animal or administration of the CLASP-7 polynucleotide consisting of the nucleic acid sequence of SEQ ID NO: 1 to an animal for treatment. (Note, this issue could be overcome by deleting the terms “pharmaceutical” and “pharmaceutically acceptable” from the claims.)

Due to the large quantity of experimentation necessary to determine an activity or property of the disclosed polypeptide such that it can be determined how to use the claimed polynucleotides encoding CLASP-7, to generate the infinite number of derivatives recited in the claims and possibly screen same for activity, and to determine the quantity of CLASP-7 polynucleotide to be administered, the most effective administration route, and the duration of

Art Unit: 1647

the treatment, the lack of direction/guidance presented in the specification regarding same and the lack of direction/guidance presented in the specification regarding the chromosomal locus of the CLASP-7 gene disclosed in the specification, the absence of working examples directed to same, the complex nature of the invention, the state of the prior art establishing that biological activity cannot be predicted based on structural similarity and the unpredictability of the effects of mutation on protein structure and function, the unpredictability of the effects of the CLASP-7 polynucleotide *in vivo* and the unpredictable nature of the locus for any isolated gene, and the breadth of the claims which fail to recite particular biological activities and also embrace a broad class of structural fragments and variants and which recite any allelic variant, undue experimentation would be required of the skilled artisan to make and/or use the claimed invention in its full scope.

6. Claims 1-4, 6-11, 14-15, and 30 are rejected under 35 U.S.C. 112, first paragraph, as containing subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor(s), at the time the application was filed, had possession of the claimed invention.

Specifically, claims 1-4, 6-11, 14-15, and 30 are directed a CLASP-7 polynucleotide wherein the polynucleotide is a polynucleotide that hybridizes under stringent hybridization conditions to (a) and encodes a polypeptide having the sequence of SEQ ID NO: 2 or an allelic variant or homologue, a polynucleotide that hybridizes under stringent hybridization conditions to (a) and encodes a polypeptide with at least 25 contiguous residues of the polypeptide of SEQ ID NO: 2, or (d) a polynucleotide that hybridizes under stringent hybridization conditions to (a)

Art Unit: 1647

and has at least 12 contiguous bases identical to or exactly complementary to SEQ ID NO: 1.

The claims also recite an isolated CLASP-7 polynucleotide comprising a nucleotide sequence that has at least 90% identity to SEQ ID NO: 1. Additionally, the claims are directed to an antisense polynucleotide less than about 200 bases in length.

The specification teaches human a CLASP-7 polynucleotide and polypeptide (SEQ ID NO: 1 and SEQ ID NO: 2, respectively). The specification also discloses that “the CLASP-7 variants of the invention can contain alterations in the coding regions, non-coding regions, or both” (pg 38, lines 19-20). The specification teaches that known methods of protein engineering and recombinant DNA technology can generate variants to improve or alter the characteristics of the CLASP-7 polypeptides (pg 39, lines 9-11). However, the specification does not teach functional or structural characteristics of the polynucleotide variants in the context of a cell or organism. The description of one CLASP-7 polynucleotide species (SEQ ID NO: 1) and one CLASP-7 polypeptide species (SEQ ID NO: 2) is not adequate written description of an entire genus of functionally equivalent polynucleotides and polypeptides which incorporate all variants and fragments (i) with at least 90% sequence identity to the human CLASP-7 polynucleotide comprising SEQ ID NO: 1. The description of one CLASP-7 polynucleotide species and one CLASP-7 polypeptide species is also not adequate written description of an entire genus of functionally equivalent polynucleotides and polypeptides which incorporate all variants and fragments (ii) that encode a polypeptide with at least 25 contiguous residues, (iii) have at least 12 bases identical to or exactly complementary to SEQ ID NO: 1, and (iv) have antisense polynucleotide less than 200 bases in length.

Vas-Cath Inc. v. Mahurkar, 19USPQ2d 1111, clearly states that “applicant must convey with reasonable clarity to those skilled in the art that, as of the filing date sought, he or she was in possession of *the invention*. The invention is, for purposes of the ‘written description’ inquiry, *whatever is now claimed*” (See page 1117). The specification does not “clearly allow persons of ordinary skill in the art to recognize that [he or she] invented what is claimed” (See *Vas-Cath* at page 1116).

With the exception of the sequences referred to above, the skilled artisan cannot envision the detailed chemical structure of the encompassed polynucleotides, and therefore conception is not achieved until reduction to practice has occurred, regardless of the complexity or simplicity of the method of isolation. Adequate written description requires more than a mere statement that it is part of the invention and reference to a potential method of isolating it. The nucleic acid itself is required. See *Fiers v. Revel*, 25 USPQ2d 1601 at 1606 (CAFC 1993) and *Amgen Inc. v. Chugai Pharmaceutical Co. Ltd.*, 18 USPQ2d 1016.

One cannot describe what one has not conceived. See *Fiddes v. Baird*, 30 USPQ2d 1481 at 1483. In *Fiddes*, claims directed to mammalian FGF’s were found to be unpatentable due to lack of written description for that broad class. The specification provided only the bovine sequence.

Therefore, only an isolated CLASP-7 polynucleotide that has the nucleotide sequence of SEQ ID NO:1 or a CLASP-7 polynucleotide that encodes a polypeptide having the sequence of SEQ ID NO: 2, but not the full breadth of the claim meets the written description provision of 35 U.S.C. §112, first paragraph. Applicant is reminded that *Vas-Cath* makes clear that the written

Art Unit: 1647

description provision of 35 U.S.C. §112 is severable from its enablement provision (see page 1115).

7. Claim 3 is rejected under 35 U.S.C. § 112, first paragraph, as containing subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor(s), at the time the application was filed, had possession of the claimed invention. The invention appears to employ novel nucleic acid molecules (i.e., clones AVC-PD23, AVC-PD24). Since the nucleic acid molecules are essential to the claimed invention they must be obtainable by a repeatable method set forth in the specification or otherwise readily available to the public. If the nucleic acid molecules are not so obtainable or available, the requirements of 35 U.S.C. § 112 may be satisfied by a deposit of the nucleic acid molecules. The specification does not disclose a repeatable process to obtain the nucleic acid molecules and it is not apparent if the nucleic acid molecules are readily available to the public. It is noted that Applicant has deposited the nucleic acid molecules (pg. 106 of the specification), but there is no indication in the specification as to public availability. If the deposit is made under the Budapest Treaty, then an affidavit or declaration by Applicant, or a statement by an attorney of record over his or her signature and registration number, stating that the specific nucleic acid molecules have been deposited under the Budapest Treaty and that the nucleic acid molecules will be irrevocably and without restriction or condition released to the public upon the issuance of a patent, would satisfy the deposit requirement made herein. If the deposit has not been made under the Budapest Treaty, then in order to certify that the deposit meets the criteria set forth in 37 C.F.R. §§ 1.801-1.809, Applicant may provide assurance of compliance by an

affidavit or declaration, or by a statement by an attorney of record over his or her signature and registration number, showing that:

- (a) during the pendency of this application, access to the invention will be afforded to the Commissioner upon request;
- (b) all restrictions upon availability to the public will be irrevocably removed upon granting of the patent;
- (c) the deposit will be maintained in a public depository for a period of 30 years or 5 years after the last request or for the effective life of the patent, whichever is longer;
- (d) a test of the viability of the biological material at the time of deposit will be made (see 37 C.F.R. § 1.807); and
- (e) the deposit will be replaced if it should ever become inviable.

Applicant's attention is directed to M.P.E.P. §2400 in general, and specifically to §2411.05, as well as to 37 C.F.R. § 1.809(d), wherein it is set forth that "the specification shall contain the accession number for the deposit, the date of the deposit, the name and address of the depository, and a description of the deposited material sufficient to specifically identify it and to permit examination." The specification should be amended to include such, however, Applicant is cautioned to avoid the entry of new matter into the specification by adding any other information.

35 USC § 112, second paragraph

The following is a quotation of the second paragraph of 35 U.S.C. 112:

The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.

8. Claims 1-4, 6-15, and 30 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.

Art Unit: 1647

9. Regarding claims 1-4, 6-15, and 30, the acronym "CLASP-7" renders the claims vague and indefinite. Abbreviations should be spelled out in all independent claims for clarity.
10. Stringency is relative, and the art does not recognize a single set of conditions as stringent. The specification also does not provide an unambiguous definition for the term. In the absence of a recitation of clear hybridization conditions (e.g., "hybridizes at wash conditions of A X SSC and B % SDS at C°C"), claims 1-4, 6-11, 14-15, and 30 fail to define the metes and bounds of the varying structures of polynucleotides recited in the claimed methods.

Claim Rejections - 35 USC § 102

The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless –

(a) the invention was known or used by others in this country, or patented or described in a printed publication in this or a foreign country, before the invention thereof by the applicant for a patent.

11. Claims 2, 4, and 12-13 rejected under 35 U.S.C. 102(a) as being anticipated by Nagase et al. (Accession No. AB037816, GenEmbl database, 14 March 2000).

Nagase et al. teach an isolated nucleic acid sequence encoding CLASP-7 of SEQ ID NO: 2 wherein the nucleic acid sequence is 100% identical to the nucleotide sequence of SEQ ID NO: 1 of the instant application (See sequence alignments attached to this Office Action as Appendix A and B). Nagase et al. also teach an antisense oligonucleotide complementary to a messenger RNA comprising SEQ ID NO: 1 and encoding CLASP-7. Please note that the claims of the instant application claim priority under 35 U.S.C. 119(e) to 13 different provisional applications. However, Applicant does not disclose the complete nucleotide sequence of SEQ ID NO: 1 or the complete amino acid sequence of SEQ ID NO: 2 of the instant application in any of the

Art Unit: 1647

aforementioned provisional applications. Therefore, the priority date of the claims that recite the nucleotide sequence (SEQ ID NO: 1) and amino acid sequence (SEQ ID NO: 2) of the instant application is determined to be 12/13/2000.

Claim Rejections - 35 USC § 103

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

This application currently names joint inventors. In considering patentability of the claims under 35 U.S.C. 103(a), the examiner presumes that the subject matter of the various claims was commonly owned at the time any inventions covered therein were made absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and invention dates of each claim that was not commonly owned at the time a later invention was made in order for the examiner to consider the applicability of 35 U.S.C. 103(c) and potential 35 U.S.C. 102(e), (f) or (g) prior art under 35 U.S.C. 103(a).

12. Claims 1, 6-11, 14-15, and 30 are rejected under 35 U.S.C. 103(a) as being unpatentable over NCI-CGAP (Accession No. AI198543; 10 November 1998; EST database) in view of Sibson et al. (WO 94/01548).

NCI-CGAP teaches an isolated that has at least 12 contiguous bases identical to or exactly complementary to SEQ ID NO: 1 of the instant application and an antisense polynucleotide less than 200 bases in length (See sequence alignment attached to this Office

Art Unit: 1647

Action as Appendix C; see nucleotides 607-3 of NCI-CGAP et al.; see nucleotides 5768-6372 of SEQ ID NO: 1 of the instant application, for example).

NCI-CGAP does not teach expression vectors, host cells, or a method of producing a polypeptide.

Sibson et al. discloses that it is generally useful to place a desired cDNA sequence into an expression vector, host cell, and express the encoded protein (see pages 8-13).

It would have been obvious to the person of ordinary skill in the art at the time the invention was made to use NCI-CGAP's DNA and the expression vector, host cell, and method of expressing and then isolating the encoded polypeptide as taught by Sibson et al. in view of Sibson's suggestion that it would be desirable to do so, as cited above.

Conclusion

The art made of record and not relied upon is considered pertinent to applicant's disclosure:

Nagase et al. DNA Research 7(1) : 65-73, 2000.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Bridget E. Bunner whose telephone number is (703) 305-7148. The examiner can normally be reached on 8:30-5:30 M-F.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Gary Kunz can be reached on (703) 308-4623. The fax phone numbers for the organization where this application or proceeding is assigned are (703) 872-9306 for regular communications and (703) 872-9307 for After Final communications.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is (703) 872-9305.

BEB
Art Unit 1647
November 6, 2002



ELIZABETH C. BUNNER
PATENT EXAMINER

RESULT 2
 AB037816 4886 bp mRNA linear PRI 14-MAR-2000
 LOCUS Homo sapiens mRNA for KIAA1395 protein, partial cds.
 DEFINITION AB037816
 ACCESSION AB037816.1 GI:7243170
 VERSION
 KEYWORDS
 SOURCE
 ORGANISM Homo sapiens brain cDNA to mRNA, clone lib:pb1uescriptII SK plus
 clone:hj07927.
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 Mammalia; Eutheria; Primates; Catarrhini; Homiidae; Homo.
 REFERENCE 1 (sites)
 Nagase,T., Kikuno,R., Ishikawa,K.I., Hiroseawa,M. and Ohara,O.
 XVI. The complete sequences of unidentified human genes.
 Prediction of the coding sequences of 150 new cDNA clones from brain which
 code for large proteins in vitro
 DNA Res. 7 (1), 65-73 (2000)
 20181126
 2 (bases 1 to 4886)
 Ohara,O., Nagase,T. and Kikuno,R.
 Direct Submission
 Submitted (31-JAN-2000) Osamu Ohara, Kazusa DNA Research Institute,
 Laboratory of DNA Technology; 1532-3 Yana, Kisarazu, Chiba
 292-0812, Japan (E-mail:cdnainfo@kazusa.or.jp,
 URL: http://www.kazusa.or.jp/huge/, Tel: +81-438-52-3913,
 Fax: +81-438-52-3914)
 FEATURES
 source
 1. .4886
 /organism="Homo sapiens"
 /db_xref="taxon:9606"
 /clone="hj07927"
 /tissue_type="brain"
 /clone_lib="pb1uescriptII SK plus"
 1. .4884
 gene

CDS
 /gene="KIAA1395"
 <1..>4884
 /gene="KIAA1395"
 /note="Start codon is not identified."
 /product="KIAA1395 protein"
 /protein_id="BA92633.1"
 /db_xref="GI:7243171"
 /translation="DARTMAASERRAFVHKINRTVAEVRKQVSRBSGSPHSSRRCS
 SSIQVPLTEVEVEPLDFEDVILSRPDAEPGLDIDVEFPADLLELLDPRRECTBERG
 IPKDEKIDQVRAVEMVITEDMVTYHRRQYISAAISPTTDPQREKQGLPQVPEQ
 DASGDERGSPDSNDSSRGSGSPDTPRSSGASSTIDLRNLADSLPILERAPED
 VDRNETLRQHRPPALLTLYPAPDEDAVERCSRPEPREHGGQILVKCSLKEI
 EIEPIFGILALDYVREKRISENTEPDNDSKGLRAGHTPAISTLAKSAIFSVT
 YSPDIEFLVILKLVLOQDISECEPYVILKEVDIAKNEKLEKLAEOFCPLG
 RYRPFAMTAVHLANIVSAGOLDSDSEGERPPATDRRRGGPODASGGDQAE
 SGFRPATLVTFNFKQEAERLSDLDLKFPLADMRPSLSLRRLRPTAOLKIDISAP
 ENPHCTLSPELLHTKPYDDPRGRPTKRIIEPPAREVYAPPTSYRNLVYPSISNFS
 RGSYRNLAIVRYQMTGEDRSQALPYIFGSSCSETRERATFYVYHNSPTEBERK
 LHLPACTVENHLLFTFYHVSQPRPETALETYVGFWTPLDHRRLRTPCLPVS
 DQPPPSVSLTPDVALPQMRWVDGKQVSEVELTAVSSVHPDQPYLDKFFTLVHLE
 GAFPERLKDVLISGNYEDELRLSLALRLASEPPLVASESHVLDLVLVIRPLIS
 GOIVNLGRGAFEMAHAVYSIVHRSLSIAEADQARGCPLAAVYHARFLPGETSLDGE
 APPTVOAATLARGSGRPASLYLARSKSISSNDPLAVAPSGYDDSRILSKLLE
 ELALQWVSSAVREAILQHMFPFOLMVKSMALHILLGORLDPKRIEPPGFLDI
 TALVSGVLEIVTVHKKDVELAEHLNLSIAPLSIDLSYDRGFVSIVRAYKQVAT
 RIQSSPNPALILTIMPETRTLCSEHYTLNIPCCDLPSPASPSVSSTTSOSTF
 SSQAPDKRVTSMFELSGFRRQHFPLAGLLTEALALEPABGALHLKKAISAVHSL
 LCGHDPDPRVYAEAVYKAVAEALYPLLSIARDLPLRLHDAEFGQRSLASLJSDT
 EGEEDIACTINPSVAMAIAGGPLAGPSRASISQPPASRAGCALSAESRLLACVL
 WYLNTEPALLQRMATDITLTPOLGLDLILYLCLAAPEYKKAFFRINSITPKSID
 MKARLEBALIGTIGARQEMVRRSERSRPFSGPENVBRMRKSVTHMKQTSDBVDKDEM
 EHEALVEGNLATAPEASIVYLDITLTYITQVNLSEARESGAVIKVLYSLGSAQSALF
 LOHGATQRLALYSKPELLEPDETELDADCLRLRSCGSRISTITTHASISYLLMR
 QNFETGHNFAKMKQVMTSSLSLVGTQNFSEHLRSLSTYLLITVAEDMDLDSIFA
 EGVQDLMNLHMLITDLYVKMKHQEDPEMLIDILYRLARGSPDLRLITWLQNMAGK
 HAEIGNHAEAAQCMVYHAA"

BASE COUNT 941 a 1605 c 1425 g 915 t
 ORIGIN

Query Match 76.6%; Score 4882.8; DB 9; Length 4886;
 Best Local Similarity 100.0%; Pred. No. 0;
 Matches 4884; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy	1	gacgcgagacacatgctgcctccgagccgcgccttcgcgcacacaaatcaacagagc	60
Db	1	GACGCGAGGACACATGCTGCTGCCAGCGCGCGCTTCGGCACAATAATCAACAGAGCG	60
Qy	61	gtggccgacagagtgcggaagcagtgctccggaagcagtgctcccccacacagc	120
Db	61	GTGGCCGACAGAGTGGGGAAGCAGGTCTCCGGGAACGAGTCTCCCGCACTCCAGC	120
Qy	121	aggcgctgcagcagcctcctgggggtcccaactgactgaagtgtcgaagccctggacltt	180
Db	121	AGGCGCTGCAGCAGCTCCTCGGGGGTCCCACTGACTGAAGTTGTGAGCCCTCGACTTT	180
Qy	181	gaggaagtactcttgagccggcgccacagatgctgagccgggccccttaaggactgta	240
Db	181	GAGGAGTACTTGTGAGCCGGCGCACAGATGCTGAGCCCGGCCCTTCAGGAGACTGTGA	240
Qy	241	gaattcccaactatgacttgagctgctgcgcagcccgccgggaatgcgcgaacagag	300
Db	241	GAATTCGCCACTATGACTTGAGCTGCTGCTGCAGCCCGCGGAAATGCCGAGACGAG	300
Qy	301	cccgagatccccaaggaatgaaaaactgtagtcccaagtgtagggccgggtgtagatgat	360
Db	301	CCCGGATCCCCAAGGATGAAAAACGTGATGCCAGGTGAGGCGCGGTGGAATGTAT	360
Qy	361	attgaagactgggtcatttccacagaaggtatcagtagtccagtgtagcacaataagccc	420
Db	361	ATTGAGGACTGGGTCAATTGCCACAGAAGGTATCACTACTGATGTCAGCATTAAGGCC	420

QY 421 gtccacacagacacacagcgagacagagagcctcccccagagcttcttgagcag 480
 DB 421 gtccacacacacacacagcgagacagagagcctcccccagagcttcttgagcag 480
 QY 481 gatgcttctgagacagagatccgagccttgagagcttcagatgaccccgagctgagc 540
 DB 481 gatgcttctgagacagagatccgagccttgagagcttcagatgaccccgagctgagc 540
 QY 541 ggcctcccgagagagacacccctcagagagagtgctcctcagaccttcagagagagc 600
 DB 541 ggcctcccgagagagacacccctcagagagagtgctcctcagaccttcagagagagc 600
 QY 601 ctggagagctgacatgctgagcctcctcctgtagagcgagcgagcccgagagatgagac 660
 DB 601 ctggagagctgacatgctgagcctcctcctgtagagcgagcgagcccgagagatgagac 660
 QY 661 cggcgagagagagacacccctcagagagagtgctcctcagaccttcagagagagc 720
 DB 661 cggcgagagagagacacccctcagagagagtgctcctcagaccttcagagagagc 720
 QY 721 gcaactgacagagatgagagcgagagagctgtagcgagccagagacaccccgagagac 780
 DB 721 gcaactgacagagatgagagcgagagagctgtagcgagccagagacaccccgagagac 780
 QY 781 ttggagacagagatgctgacagctgctgctgtagagctgagagctgagagctgagc 840
 DB 781 ttggagacagagatgctgacagctgctgctgtagagctgagagctgagagctgagc 840
 QY 841 atcttgagagatgctgctgtagatgtagagagagagagagagagagagagagagagc 900
 DB 841 atcttgagagatgctgctgtagatgtagagagagagagagagagagagagagagagc 900
 QY 901 tacttgagagatgctgagagctgagagagagagagagagagagagagagagagagc 960
 DB 901 tacttgagagatgctgagagctgagagagagagagagagagagagagagagagagc 960
 QY 961 gcaactgacagagatgagagcgagagagctgtagcgagccagagacaccccgagagac 1020
 DB 961 gcaactgacagagatgagagcgagagagctgtagcgagccagagacaccccgagagac 1020
 QY 1021 ttcttgagagatgctgagagagagagagagagagagagagagagagagagagagc 1080
 DB 1021 ttcttgagagatgctgagagagagagagagagagagagagagagagagagagagc 1080
 QY 1081 ccttgagagatgctgagc 1140
 DB 1081 ccttgagagatgctgagc 1140
 QY 1141 ggcctcccgagagagacacccctcagagagagtgctcctcagaccttcagagagagc 1200
 DB 1141 ggcctcccgagagagacacccctcagagagagtgctcctcagaccttcagagagagc 1200
 QY 1201 acgagc 1260
 DB 1201 acgagc 1260
 QY 1261 tcgagc 1320
 DB 1261 tcgagc 1320
 QY 1321 ggcagc 1380
 DB 1321 ggcagc 1380
 QY 1381 acagc 1440
 DB 1381 acagc 1440
 QY 1441 gctgagc 1500
 DB 1441 gctgagc 1500
 QY 1500 gctgagc 1560
 DB 1500 gctgagc 1560

DB 1501 aagatcgagc 1560
 QY 1561 catatcaagc 1620
 DB 1561 catatcaagc 1620
 QY 1621 ggcagc 1680
 DB 1621 ggcagc 1680
 QY 1681 agcctcaactcaagc 1740
 DB 1681 agcctcaactcaagc 1740
 QY 1741 atgagc 1800
 DB 1741 atgagc 1800
 QY 1801 gaattacagc 1860
 DB 1801 gaattacagc 1860
 QY 1861 gagc 1920
 DB 1861 gagc 1920
 QY 1921 ttcttgagc 1980
 DB 1921 ttcttgagc 1980
 QY 1981 acttgagc 2040
 DB 1981 acttgagc 2040
 QY 2041 tctgagc 2100
 DB 2041 tctgagc 2100
 QY 2101 atgagc 2160
 DB 2101 atgagc 2160
 QY 2161 ggcagc 2220
 DB 2161 ggcagc 2220
 QY 2221 ggcagc 2280
 DB 2221 ggcagc 2280
 QY 2281 ctgagc 2340
 DB 2281 ctgagc 2340
 QY 2341 ggcagc 2400
 DB 2341 ggcagc 2400
 QY 2401 atgagc 2460
 DB 2401 atgagc 2460
 QY 2461 ggcagc 2520
 DB 2461 ggcagc 2520
 QY 2521 ggcagc 2580
 DB 2521 ggcagc 2580
 QY 2581 acagc 2640
 DB 2581 acagc 2640

A cont.

Mon Oct 7 12:35:11 2002

us-09-736-968a-1.rge

A cont.

8-D

Qy	4801	ctgacctggttgcagaac:ntgycgcggaagcagcggagcttggcgaaccacgcgcgagggcc	4860
Db	4801	ctgacctggttgcagaac:ntgycgcggaagcagcggagcttggcgaaccacgcgcgagggcc	4860

QY	4861	gccca	gtg	cat	gtg	ca	cgc	gcgc	4886
Db	4861	gccca	gtg	cat	gtg	ca	cgc	gcgc	4886

RESULT 3
BC008335

100

seq_name: gb_pr:AB037816
 seq_documentation block:
 LOCUS AB037816 4886 bp mRNA linear PRI 14-MAR-2000
 DEFINITION Homo sapiens mRNA for KIAA1395 protein, partial cds.
 ACCESSION AB037816
 VERSION AB037816.1 GI:7243170
 KEYWORDS
 SOURCE Homo sapiens brain cDNA to mRNA, clone_11b:pbunescriptii SK plus

ORGANISM Homo sapiens
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
 REFERENCE 1 (sites)
 Nagase, T., Kikuno, R., Ishikawa, K.I., Hirasawa, M. and Ohara, O.
 Prediction of the coding sequences of unidentified human genes.
 XVI. The complete sequences of 150 new cDNA clones from brain which
 code for large proteins in vitro
 DNA Res. 7 (1), 65-73 (2000)
 JOURNAL MEDLINE 2 (bases 1 to 4886)
 20181126
 Ohara, O., Nagase, T. and Kikuno, R.
 Direct Submission
 Submitted (31-JAN-2000) Otsu Ohara, Kazusa DNA Research Institute,
 Laboratory of DNA Technology, 1532-3 Yana, Kisarazu, Chiba
 292-0812, Japan (E-mail:cdna@kikazusa.or.jp)
 URL: http://www.kazusa.or.jp/huge/, Tel.: +81-438-52-3913,
 Fax: +81-438-52-3914)
 FEATURES
 Location/Qualifiers
 1..4886
 /organism="Homo sapiens"
 /db_xref="taxon:9606"
 /clone="h07927"
 /tissue_type="brain"
 /clone_lib="pbunescriptii SK plus"
 1..4884
 /gene="KIAA1395"
 <1..>4884
 /gene="KIAA1395"
 /note="Start codon is not identified."
 /codon_start=1
 /product="KIAA1395 protein"
 /protein_id="BA92633.1"
 /db_xref="GI:7243171"
 /translation="DARTMAASERRAPAHKINTVAENVKQVSRSSGSPSSRRCS
 SSIQVPLEVEVDFEDVLLSRPDAEPGLRDVLEPPADDELLQRECRTEPG
 IKPDKELDAOVAAYEMVIEDWVIVHRYOYLSSAAYSPVTDYQROGLEROVEQ
 DASGDERSGPDSNDSRRSGSPEDTPRSAGASIFDLNMLADSLPGLERAPEQ
 VDRNETLRQHRPALLITLYPAPDEDEAVERCSPREPREGORLIVKCLSRFEI
 ETEPIEGTILAYDVERKKISINENYFPLNDSMKGLRAHGHAPALSTLARSATFSY
 YSPDPIFVITKEVILQGGDISECCPEYVILKEVDPAKNEKLEKTLAEOCRIG
 RYRMPFAPVAVHIANIVSSAGLDRODSGGERPAPTPDRRRGPDRAASDQACSP
 SGFRATUTLVNFPKQKABERSDDELKFLADRRSSLLRRPTATOLKIDISAP
 ENHPCLSPELHLITPTDPRGRPTKEILEPAREVAFPTSTRLIIVPHSLNFS
 RQGSVKNLAVERVYGTGEDPSQALPVIKGSQSEPTREAFVTVVHNKSPETEFK
 LHPACVYENHLLLETFYHVSQCPRGTALETVPVGTWIPLOHRLRGLPCLPVS
 DQPPSYVLEPDAVLPGRMWDGKGVSVLETAASSVPDOPYLDFKFTLVHLEE
 GAFPRKLDVYSEGNVEOELRASILALRLASPEPLVAFSHVLDKLVLRIPPLIS
 GOIVNLRGAEFMAHVVYSLVRSLEAODRGHQPOLAVYAFRLGTETSPSPDG
 APPVYQAAITTLARSGSPASLYLARSKSSISNPDILAVAGSVDDRVSHILASKE
 ELALQWYSSSAVREAITIQHAFPPQALVYSMALHLLGORDLTPPKLRPGREDDI
 TALVSVGLGVITRVHNDVEIAEHUNSLAFILSDLSLVDRGFVSLVRAHKKOYAT
 RLQSSNPAPALITLMETFRILCSHEHYVTLNIPCCPLSPASPSVSSTISQSTF
 SSQADDPKVTSMFELSGPRQOHLFAGLLITELALALEPAEAGFLLHKALISAVSL
 LCGHDPRTYAEATVKARVAELYLPLLSIADTLPRLHDEAGPQGRSRIASMLSDT
 EGGDLAGTINPSVMAIAGGPLAGSASISQGPASRAGCALAESSTRLACVL
 WYLNKTEPALQRMATDLTLPOLGRLDLYLCLAAEYKGAAPRISLTFKESLD
 MKARLEALIGTIGAROMVRSRERSRSPGPEVWRKRGVTHMKQDSRVKTDDEM
 EHBALVEGTLATEASIVYDTLEIYIYOVVHLSARESVLCAVYKYVLYSLGSNQAIF
 LQHGATOKALVSKFPELLFEDTELCAIDLRLRLRGSRISTITLHSAISILMKR
 QNFEGHNFAARKVQVNTSLISLVGTQNFSEHLRSLTTLITVAEDMGRLDSTFA
 EOVDLMFLHMLITDIYVKKMKHQDEPMILDMYRIARQYQSPDLRLTWLQNAK
 HALEGNHAEAAQCWTHAA"

BASE COUNT 941 a 1605 c 1425 g 915 t
 ORIGIN

alignment_scores:
 Quality: 8334.00 Length: 1624
 Ratio: 5.135 Gaps: 0
 Percent Similarity: 99.938 Percent Identity: 99.938

alignment_block:
us-09-736-968a-2 x AB037816 ..

Align seg 1/1 to: AB037816 from: 1 to: 4886

```
1 MetAlaIaSerGIuArGAlaIaPheAlaIaHisLysIleAsnArgThrVa 17
  |||
13 ATGGCTGCTCCGAGCGCGCGCTTCGCGCAAGATCAACAGAGCGAGT 62
  |||
17 LalaAlaIaGluValArgLysGluValSerArgLysArgSerGlySerProH 34
  |||
63 GCGCCGAGAGTGGCGAGAGAGGTGCCGGAGACGAGTGGCTCCCCC 112
  |||
34 IIsSerSerArgArgCysSerSerSerLeuGlyValProLeuThrGluVal 50
  |||
113 ACTCCAGACAGGCGCTGACAGAGCTCCCTGGGGTCCCACTGACTGAGTT 162
  |||
51 ValGIuProLeuAspPheGluAspValLeuLeuSerArgProAspAl 67
  |||
163 GTGAGCGCCCTGGACTTTSAGATGACTTTCAGCCGCCACAGATGC 212
  |||
67 agIuProGlyProLeuArgAspLeuValGluPheProAlaAspAspLeuG 84
  |||
213 TGAGCGCGGCGCCCTCAG3AGCTGGTAGAATGCCAGCTGATGACTTGG 262
  |||
84 IuLeuLeuLeuGluProArgGluCysArgThrThrGluProGlyTLePro 100
  |||
263 AGCTGCTGCTGCGAGCCCGGAGATGCCGAGACAGAGCGCGGATGCC 312
  |||
101 LysAspGluLysLeuAspAlaGluValArgAlaAlaValGluMetLysL 117
  |||
313 AAGGATGAAAAACTGGATGCCAGTGGAGCGCGCGTGGAGATGATAT 362
  |||
117 eGIuAspTPValIleValHisArgArgTyrLysLysSerAlaAlaIa 134
  |||
363 TGAGGAGCTGGGTATTGTCCACGAGAGTATCAGTCTGAGTGCAGAT 412
  |||
134 YSerProValThrThrAspThrGluArgGluArgGluLysGlyLeuPro 150
  |||
413 ACAGCCCGCGTACCACAGACACAGCGGAGAGAGAGAGGCGCTCC 462
  |||
151 ArgGluValPheGluGluAspAlaSerGlyAspGluArgSerGlyProG 167
  |||
463 CGCAGAGCTTTGAGCAGATGCTTCTGGAGACGAGAGGTCCGCGCA 512
  |||
167 uAspSerAsnAspSerArgArgGlySerGlySerProGluAspThrPro 184
  |||
513 GGACTGGAATGACTCCCGCGGTGCTCGCGGCTCCCGGAGAGACCC 562
  |||
184 rSerSerGlyAlaSerSerIlePheAspLeuArgAsnLeuAlaAsp 200
  |||
563 GAAGCAGATGGTCTTACATCTTGCACCTGAGGAACTGGCAGCTGAC 612
  |||
201 SerLeuLeuProSerLeuLeuGluArgAlaAlaProGluAspValAsp 217
  |||
613 TCATTTGCTGCTCTGCTAGAGCGGCGGCCCGAGAGATGTGAGCCG 662
  |||
217 gArGAsnGluThrLeuArgArgGluHisArgProProAlaLeuLeuThr 234
  |||
663 GCGCAATGAACCTTCGAGCGGAGACCGCGCCCGGCTGCTACACC 712
  |||
234 eUtyrProAlaProAspGluAspGluAlaValGluArgCysSerArgPro 250
  |||
713 TCTACCGGAGCTGACGAGAGAGAGCGCTGAGACGCTGTAGCCGCC 762
  |||
251 GluProProArgGluHisPheGlyGluValGluValLysCysLeuSe 267
  |||
763 GAGCAGACCGCGAGCAGCTTGCACAAAGAGATCTTGTCAAGTGTCTGC 812
  |||
267 rLeuLysPheGluIleGluIleGluProIlePheGlyIleLeuAlaLeu 284
  |||
  GCTCAAGTTGAGATTTGAATTTAGGCCCATTTTGGGATCTTGGCTGT 862
```

```
284 YrAspValArgGluLysLysLysIleSerGluAsnPheTyrPheAspLeu 300
  |||
863 ATGATGTGGCGGAGAAAAAGAGATCTCGAGAGAACTTCACTTGCAGCTG 912
  |||
301 AsnSerAspSerMetLysGlyLeuLeuArgAlaHisGlyThrHisProAl 317
  |||
913 AACTCGACTCCATGAGAGGGGCTTGGGCTCATGGACACCCCTGC 962
  |||
317 AlIeSerThrLeuAlaArgSerAlaIlePheSerValThrTyrProSer 334
  |||
963 CATCTCCACCTGGCCCGCTGCGCATCTCTGTGACCTACCCCTCAC 1012
  |||
334 rAspAlIePheLeuValIleLysLeuGluLysValLeuGluGluLysAsp 350
  |||
1013 CTGACATCTTCTGCTCATCAAGATTGAGAGGTTCTTACCAAGGGGAG 1062
  |||
351 IIsSerGluCysCysGluProTyrMetValLeuLysGluValAspThrAl 367
  |||
1063 ATCAGTGAATGCTGTGAGCTTACATGCTGTGAAAAGATGGACACAC 1112
  |||
367 aLysAsnLysGluLysLeuGluLysLeuArgLeuAlaGluIlePheC 384
  |||
1113 CAAGAAACAAGAGAAAGTAAAGAAAGCTGCGCTGGCGCGAGCAGTTCT 1162
  |||
384 YsThrArgLeuGluValTyrArgMetProPheAlaThrThrAlaValHis 400
  |||
1163 GCACCGCGCTGGCGCGCTACCGCATGCTTCCCTTGGAGCGCGCTGCAC 1212
  |||
401 LeuAlaAsnIleValSerSerAlaGlyLeuAspArgAspSerAspSe 417
  |||
1213 TTGGCCAAATCGTGAAGCAGCGCTGGAGCTGACGCGAGCTGTGACTC 1262
  |||
417 rGluGluArgArgArgProAlaThrThrAspArgArgArgGlyProG 434
  |||
1263 GAGAGCGAGCGCGCGCAGCTGAGACAGCGCGCGCTGGGAGCGCC 1312
  |||
434 IuAspArgAlaSerSerGlyAspAspAlaCysSerPheSerGlyPheArg 450
  |||
1313 AGGACCGGCGAGTGTGGGAGCAGCGCTGACGCTTCTGCGCTTCGCT 1362
  |||
451 ProAlThrLeuThrValThrAsnPheLysGluGluValGluValGle 467
  |||
1363 CCAGCCAGCTTAAGTCTCAAAACTTCTTAAAGCAGAGGCTGAGCACT 1412
  |||
467 uSerAspGluAspPheLysPheLeuAlaAspMetArgArgProSer 484
  |||
1413 CAGTGAAGAGAGCTTCAAGTCTCTGCTGACATGAGGCGCGCTCGT 1462
  |||
484 rLeuLeuArgArgLeuArgProValThrAlaGluLeuLysIleAspIle 500
  |||
1463 CCCTGCTGGGAGACTACGCTCTGAGCTGCCCAAGTCAAGATGAGATT 1512
  |||
501 SerProAlaProGluAsnProHisPheCysLeuSerProGluLeuLeu 517
  |||
1513 TCTCCGCTCTGAAATGCCACATTTGCTGCTCTCCCTGAGCTGCTCA 1562
  |||
517 sIleLysProTyrProAspProArgGlyArgProThrLysGluLeuG 534
  |||
1563 TATCAAGCCCTTACCCGAGACCCAGAGGCGCGGCCACCAAGAGATTCTGG 1612
  |||
534 IuPheProAlaArgGluValTyrAlaProHisThrSerTyrArgAsnLeu 550
  |||
1613 AGTTCCCGCGCGAGAGTCTTGGCCCCCATACAGCTTACAGAGACTG 1662
  |||
551 LeuTyrValTyrProHisSerLeuAsnPheSerSerArgGlnLysSer 567
  |||
1663 CTGTAGCTTACCCGACACAGCTTCAACTTCAAGACCGCGCGCTCGCT 1712
  |||
567 IArgAsnLeuAlaValArgValGluTyrMetThrGlyGluAspProSer 584
  |||
1713 GCGCACTTCTGCTGCGAGTCAATGACATGACAGAGAGAGAGAGAGCC 1762
  |||
584 IuAlaLeuProValIlePheGlyLysSerSerCysSerGluPheThrArg 600
```

B cont.

B cont.

```
|||||
1763 AGGCTGTGGCGGTCATCTTGGCAAGTCCAGCTGCAGTGAATTATCCCGC 1812
601 GUAlaPheThrProValValThrHisAsnLysSerProGluPheTyrGI 617
|||||
1813 GAGGCTTCACACCGGTCGTACCATTAACAGTCCCGGATTTCAACA 1862
617 uGIuPheLysLeuHisLeuProLacCysValThrGluAsnHisLeu 634
|||||
1863 GGAGTTCAGAGCTGCATCTTCACAGCTGCTGACAGAGAACCATCACCCTGC 1912
634 euPheThrPheTyrHisValSerCysGlnProArgProGlyThrAlaLeu 650
|||||
1913 TGTTCACCTTCTACATGTTCAGCTGCAGCCCGGCGGACACTGGCCTG 1962
651 GIuThrProValGIuPheThrTTPileProLeuLengLHisGlyArgLe 667
|||||
1963 GAGACACCGCGGGCTTTACTTGATGCCACCTGTCGACAGCAGGCGCCT 2012
667 uATGTHTGIuProPheCysLeuProValSerValAspGlnProProPro 684
|||||
2013 GAGGACCGGCGCCTTCTGTCTCCAGTGTGTGTGGACACGCGCGCCCA 2062
684 eTyrSerValLeuThrProAspValAlaLeuProGlyMetArgTyrVal 700
|||||
2063 GCTATTCCGTCACACCGCATGTGGCGCTCCGGGCGATGCGCTGGGTG 2112
701 AspGluHisLysGlyValPheSerValGluLeuThrAlaValSerSerVa 717
|||||
2113 GAGCGTCACAGAGGCGGTTCAGTGTGAGCTCAGGCGGTGTCTCTGT 2162
717 HisProGlnAspProTyrLeuAspLysPhePheThrLeuValHisVal 734
2163 GCACCCCGACAGACCCCTACCTGGACAAATCTTCACCCGTGTGACGTCC 2212
734 euGIuGIuGIuAlaPheProPheArgLeuLysAspThrValLeuSerGIu 750
|||||
2213 TGGAGGGAGGAGCTTCCCATTCGCGCTCAAGGACACTGTCTGAGGAG 2262
751 GIuAsnValGIuGlnGluLeuArgAlaSerLeuAlaAlaLeuArgLeuAl 767
2263 GGCACGTCGAGACAGAGCTGGCGGCGAGTCTTCACACTGCGCCTGGC 2312
767 aSerProGluProLeuValAlaPheSerHisHisValLeuAspLysLeu 784
2313 CACGCCCGAGACCCCTGTGTGACCTTCTCCACACAGCTGTGACAAAGCTG 2362
784 aLArgLeuValLLeArgProProLLeLLeSerGIuLLeValAsnLeu 800
|||||
2363 TGGCTGTGGTATCAGGCCCCCGATCATCATGTCGACAGATTGTGAACCTG 2412
801 GIuArgGIuAlaPheGluAlaMetAlaHisValValSerLeuValHisAr 817
2413 GGCCTGTGAGACCTTTGAAGTAATGGCCCATGTACAGCTTGTTCACCG 2462
817 gSerLeuGIuAlaAlaGlnAspAlaArgGIuHisCysProGlnLeuAla 834
2463 GAGCGTCGAGAGCAGCCAGSMTGCCCGGCTCACTGGCCACAGCTGGCTG 2512
834 IaTyrValHisTyrAlaPheArgLeuProGlyThrGIuProSerLeuPro 850
2513 CTTACGTCCACTACGCTTTCGCTCTGCTGACACTGAGCCAGCCTCCCG 2562
851 AspGIuAlaProProValThrValGIuAlaAlaThrLeuAlaArgLysE 867
2563 GATGGGGCCCTCCAGTGAAGTGCAGAGCTGCCACTGGCCCTGGCTC 2612
867 rGIuArgProAlaSerLeuTyrLeuAlaArgSerLysSerLLeSerSers 884
2613 TGGTGCCTCCGACAGCTCTACCTGCGCGGTTCACAGAGCATCAGACACA 2662
884 eRAsnProAspLeuAlaValAlaProGlySerValAspAspGIuValSer 900
|||||

2663 GCAACCTGACCTGCGCGTGGCCCTGGCTCTGTGATGACAGGTTTCC 2712
901 ArgTLeuAlaSerLysLeuLeuHisGIuGluLeuAlaLeuLInTyrPa 917
|||||
2713 CGCATCTGGCGCAGCAAGCTTCACAGAGAGCTGGCTGTGAGTGGT 2762
917 ValSerSerSerAlaValArgGIuAlaLLeuGlnHisAlaTyrPheP 934
2763 GGTACAGCAGAGTGCCTACGCGAGGCGCATCTCCAGCAGCCCTGTTCT 2812
934 hePheGlnLeuMetValLysSerMetAlaLeuHisLeuLeuGlyGIu 950
2813 TCTTCCAGCTCAGTGTGAAGATATGCGCTGCACCTGCTGTGGCGAC 2862
951 ArgLeuAspThrProArgLysLeuArgPheProGlyIuArgPheLeuAsp 967
2863 CGACTGACACACCCCGCAAGCTGTGCTTCCCGAGCGTTCCTGGACGA 2912
967 PileThrAlaLeuValGIuSerValGIuLeuGIuValLLeThrArgValH 984
2913 CATCACTGCTTGTGGTGGCTGTGTGGCGCTGAGAGTATCACCGGTGTC 2962
984 IsLysAspValGIuLeuAlaGIuHisLeuAsnAlaSerLeuAlaPhePhe 1000
2963 ACAAGGATGTGAGCTGGCCGAGACCTCAACGCGACCTGGCTTGTCTC 3012
1001 LeuSerAspLeuLeuSerLeuValAspArgGIuPheValPheSerLeuVa 1017
3013 CTCAAGTACCTTCTGTCTCTGTGTGGACCGGGGCTTTCCTTCAGCTGTG 3062
1017 ArgAlaHisTyrLysGlnValAlaThrArgLeuGlnSerSerProAsn 1034
3063 CCGGGCCCATACAAAGCAGGTGGCCACGCGCTCACTGACGCTTCATC 3112
1034 roAlaAlaLeuLeuThrLeuArgMetGIuPheThrArgLLeuCysSer 1050
3113 CAGAGGCTGTGTACCTCGCGCATGGAAATTCACCCCATCTGTGAGC 3162
1051 HisGlnHisTyrValThrLeuAsnLeuProCysCysProLeuSerProP 1067
3163 CACGAGCAGTACAGTACCTCAACCTCCCGTGCCTGCGCCCTGTACCTGC 3212
1067 oAlaSerProSerProSerValSerSerThrThrSerGlnSerSerThrP 1084
3213 AGCTCCGCCCTCCCTCTGTGTCTCCACACCTCCAGAGCTCAACT 3262
1084 heSerSerGlnAlaProAspProLysValThrSerMetPheGluLeuSer 1100
3263 TCTCCAGCAAGCCCGGACCCCAAGGTGACCAAGATGTTGAAGTGAAGT 3312
1101 GIuProPheArgGlnGlnHisPheLeuAlaGIuLeuLeuLeuThrGIuLe 1117
3313 GGACCATTCGCGAGCAGACACTTCTAGCTGGGCTCCGCTGAGAGGAGCT 3362
1117 uAlaLeuAlaLeuGluProGIuAlaGIuGIuAlaPheLeuLeuHisLysL 1134
3363 GGCACCTGGCCCTCGAACCTGAGCTGAAGGGGCTTCCTGTGGACACAGA 3412
1134 yAlaAlaLLeSerAlaValHisSerLeuLeuCysGIuHisAspThrAspPro 1150
3413 AGGCAATCAGTGTGTGACAGCTGCTATGTGGCCATGACATGACACCC 3462
1151 ArgTyrAlaGIuAlaThrValLysAlaArgValAlaGIuLeuTyrLeuP 1167
3463 CGCTACGCGGAGGCGACATGTGAAGCTGTGTGGCGAGCTGTACCTGCC 3512
1167 oLeuLeuSerLLeAlaArgAspThrLeuProArgLeuHisAspPheAlaG 1184
3513 ACTGCTTTCGATTCACGGGATACCTTGGCCAGCGCTGATACACTTGTGCT 3562
1184 LuGIuProGIuGIuLArgSerArgLeuAlaSerMetLeuAspSerAspThr 1200
3563 AGGCGCCAGGTGACGGTCAAGACTGGCTCAAGTCTTGACTCAGACACA 3612
```

Mon Oct 7 12:35:17 2002

us-09-736-968a-2.rge

B cont.

1201 GluGlyGluGlyAspIleAlaGlyThrIleAsnProSerValAlaMetAl 1217
1217 aIleAlaGlyGlyPrcIleAlaProGlySerArgAlaSerIleSerGng 1234
3663 CATGGTGGTGGCCCTTACGCCCTGGCTCCGGGCGAGATCTCCAGG 3712
1234 lypProThrAlaSerArgAlaGlyCysAlaLeuSerAlaGlySer 1250
3713 GGCACCAACGGCTTCGCGAGGCTGTGCCCTCTGCTGAGTCAAC 3762
1251 ArgThrIleuAlaCysValIleuThrValIleuIysAsnThrGluProAl 1267
3763 CGGACCTTCTGGCTGTGTCTGTGGGTGCTGAAAAACCGAGCCGCC 3812
1267 AleuLeuGlnArgTrpIleThrAspIleuThrIleuProGlnIleuGlyArgL 1284
3813 GCTCTGACAGCCCTGGCCACTGACTGACTGACCTCCCGACGCTGGAGCTC 3862
1284 euleuAspIleuThrLeuGlyCysLeuAlaAlaPheGlyIleuGlyLys 1300
3863 TGTGGACTGCTGTACCTTGTGCTGCTGTGCTGTGAGTCAAGGGGAA 3912
1301 LysAlaPheGluArgIleAsnSerIleuThrPheIysIysSerLeuAspHe 1317
3913 AAGGCTTGTGAAGCATACACAGCTCACATCAAAAATCTCTGATAT 3962
1317 LysAlaArgLeuGluGluAlaIleLeuGlyThrIleGlyAlaArgGng 1334
3963 GAGGGCGGCTAGAGAGAGCCATCTGGGACATCGAGCTCGACAG 4012
1334 lueValArgArgSerIleGluIleuArgSerProPheGlyAsnProGluAsn 1350
4013 AAATGGTTCGGCGAAGTCGTGAGAGAGAGCCGTTGGGATCCAGAGAAC 4062
1351 ValArgTrpArgLysSerValThrHisTrpIysGlnThrSerAspArgVa 1367
4063 GTGGCTGGCGGAGAGAGCTCACACACTGAGAGAGAAACCTCACAGCCGCT 4112
1367 lAspIysThrLysAspGlyMetGluHisGluAlaLeuValGluGlyAsnL 1384
4113 GGCACAGACCAAGATGAAATGGAACAGAGCCCTGTGTGAAGGAGAAC 4162
1384 eulAlaThrGluAlaSerLeuValValLeuAspThrIleuGluIleIleVal 1400
4163 TGGCAACCGAGCAAGCCAGTGTCTGGACACACTGGAGATCATCGTG 4212
1401 GluThrValMetLeuSerGluAlaArgIleuSerValIleuGlyAlaValle 1417
4213 CAGACGCTATGCTTTCAGAAAGCCGGAGAGCGCTCTGGGGGAGATGCT 4262
1417 ulysValIleuThrLysSerLeuGlySerAlaGlnSerAlaLeuPheLeuG 1434
4263 GAAAGTGTGTGTACAGCTGGGGAGTGCACAGAGTCCCTCTCTTGC 4312
1434 lnhIsgIleuAlaThrGlnArgAlaLeuValSerLysPheProGluLeu 1450
4313 AGCATGGCTGGCCACCCAGAGGGCCCTGTGTCAAGTTCGCGAGCTG 4362
1451 LeuPheGluGluAspThrGluLeuGlyAlaAspIleuGlySerLeuIleu 1467
4363 CTGTTCGAGAGAGACACGAGGTGTGTGTGTGTGTGTGTGTGTGTGTGT 4412
1467 uArgHisCysGlySerArgIleSerThrIleArgThrHisAlaSerAlas 1484
4413 ACAGACACTGTGGACCGCATCAGCACCATCCGACACGACGAGCGCT 4462
erLeuThrLeuLeuMetArgGlnAsnPheGluIleGlyHisAsnPheAla 1500
CTGTACCTGGCTCATGGGAGAGAACTTCGAGATCGGCGACAACTTTGCC 4512

1501 ArgValIysMetGluValThrMetSerLeuSerSerLeuValGlyThrTh 1517
4513 CGTGTGAAGATGCAGGATCACCATGTCTCTGTGTGTGTGTGTGTGTGTGT 4562
1517 rGlnAsnPheSerGluGluHisIleuArgArgSerLeuIleuThrIleuThr 1534
4563 GCAGAACTTCAGTGAAGAGACACTGCGAGCTTCACTCAAAACATCTCA 4612
1534 hrTyAlaGluGluAspMetGlyLeuArgAspSerThrPheAlaGluGln 1550
4613 CCTATGCTGAGAGAGACATGGGCTGTGGGACAGCAGCCTTGGCAGAGCAG 4662
1551 ValGlnAspLeuMetPheAsnLeuHisMetIleuThrAspThrVally 1567
4663 GTCCAGAGACTGATGTTCAAACCTGCACATGATCTGACGAGGACAGTGAA 4712
1567 sMetIysGluHisGluGluAspProGluMetLeuIleAspLeuMetTyra 1584
4713 GATGAGGAAACACAGAGAGACCTGAGATGCTCATTCACCTCATGTACA 4762
1584 rGlyIleAlaArgGlyTyrgIleGlySerProAspLeuArgIleuThrIleu 1600
4763 GAATTGGCCCGGGGCTACACAGGGCTCACCGGACCTTCGGCTGAGCTGTG 4812
1601 GlnAsnMetAlaGlyLysHisAlaGluLeuGlyAsnHisAlaGluAlaAl 1617
4813 CAGAACTGTGGCCGGGAGAGCAGCGGAGCTGGGCAACACGCGGAGGCGC 4862
1617 agIleCysMetValHisAlaAla 1624
4863 CCAATGCTATGTGTGCAGCGGC 4884

Oy	5578	ttcaacgcggagttgaggcgcaacacggggagctgcgcacggaacaaacagatgaagacgtg	5637
Db	794	tttccgcccgaattgggcccgcacacgsgaagttgccccagacaccacgaacttgaagcgtgcg	735
Oy	5638	ctcagcacgcagcaacgcctctccctcaatcaaacgtgcacccgtgtgtgcacacggag	5697
Db	734	tttaaga-cgacacacgcctttcccttcaacaaagactgcactgcgtatgctcca-cggagag	677
Oy	5698	gagacgctgtcctgaagcagctgagagtggtgcacatagagacaatgcagaagaacacggag	5757
Db	676	gaacgcgttttaagcccaatggagagtggtgcactccagacatccagaaagaaacacggagag	617
Oy	5758	ctgagccttgcacacgcagcagaacccacacagatgctaagatgtcacagatggtctcaag	5817
Db	616	tttgccctttt-ccacccgacgacgagacccacacagatgctaaagatgcctacagatgctgcttcag	558
Oy	5818	gagctcgtgaagggccacacgtgaaacacaggtgtccctcgagagtggtgcacagatgtttttaga	5877
Db	557	ggctctgtagggccacacgtgaaacacaggtgtccctcgagagtggtgcacagatgtttttaga	498
Oy	5878	gagatcccggaagaccccaagctctctccggatcaacaacaaatgtgcctgtgttcaag	5937
Db	497	gaatctcccggaagaccccaagctctctccggatcaacaacaaatgtgcctgtgttcaag	438
Oy	5938	gactctcgaagaatgtgtaggtgtgcctgcggaacaaataagagccctgattgtgcccagac	5997
Db	437	gaattctgcaagaatgtgtaggtgtgcctgcggaacaaataagagccctgattgtgcccagac	378
Oy	5998	cagaagagatcacacacgtgtgagctgtagagcgcaactctgtgcgctgtggagagctctgac	6057
Db	377	caaaagagatcacacacgtgtgagctgtagagcgcaactctgtgcgctgtggagagctctgac	318
Oy	6058	cccctcttaaccagcgcctctgcgcacagctgattgtagcaacccacacccacgcctctcaagac	6117
Db	317	cccctcttaaccagcgcctctgcgcacagctgattgtagcaacccacacccacgcctctcaagac	258
Oy	6118	tcctttgacaagsgcaagtttccgaagcgacagccctctgaagcccaagaagccaagctgt	6177
Db	257	ttcctttacaagsgcaagtttccgaagcgacagccctctgaagcccaagaagccaagctgt	198
Oy	6178	acctagaaggaaacagcaccgcgggacctcaagctgtctgtgtcgtcgaggggaatctgtccctg	6237
Db	197	acctagaaggaaacagcaccgcgggacctcaagctgtctgtgtcgtcgaggggaatctgtccctg	138
Oy	6238	tgccacatggagctgtgggtgtgacacaaactgtactgtgggtgtgggcctctgcgcccgtgt	6297
Db	137	tgccacatggagctgtgggtgtgacacaaactgtactgtgggtgtgggcctctgcgcccgtgt	78
Oy	6298	ccccatctgtgcacatgtatcttcctccctttttaaatttaaatgtttttataga	6357
Db	77	ccccatctgtgcacatgtatcttcctccctttttaaatttaaatgtttttataga	18
Oy	6358	aaaaaaaaaaaaa	6372
Db	17	aaaaaaaaaaaaa	3